Design Therapeutics, Inc. (NASDAQ:DSGN) Receives Consensus Recommendation of “Hold” from Analysts

Shares of Design Therapeutics, Inc. (NASDAQ:DSGN) have been given an average recommendation of “Hold” by the seven brokerages that are presently covering the company, MarketBeat.com reports. Seven research analysts have rated the stock with a hold recommendation. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $5.50.

A number of equities research analysts recently weighed in on the company. Royal Bank of Canada restated a “sector perform” rating and set a $4.00 price objective on shares of Design Therapeutics in a research report on Wednesday, March 20th. Wedbush restated a “neutral” rating and set a $5.00 price target on shares of Design Therapeutics in a report on Wednesday, March 20th.

Insider Buying and Selling at Design Therapeutics

In related news, Director John P. Schmid acquired 17,809 shares of the stock in a transaction dated Monday, March 25th. The stock was bought at an average cost of $3.74 per share, for a total transaction of $66,605.66. Following the completion of the transaction, the director now directly owns 26,965 shares of the company’s stock, valued at $100,849.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director John P. Schmid acquired 9,156 shares of the firm’s stock in a transaction dated Friday, March 22nd. The stock was bought at an average cost of $3.62 per share, for a total transaction of $33,144.72. Following the completion of the transaction, the director now directly owns 9,156 shares in the company, valued at approximately $33,144.72. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director John P. Schmid bought 17,809 shares of the stock in a transaction that occurred on Monday, March 25th. The shares were purchased at an average cost of $3.74 per share, with a total value of $66,605.66. Following the purchase, the director now directly owns 26,965 shares of the company’s stock, valued at $100,849.10. The disclosure for this purchase can be found here. Corporate insiders own 27.80% of the company’s stock.

Institutional Trading of Design Therapeutics

A number of large investors have recently bought and sold shares of DSGN. Pale Fire Capital SE bought a new stake in shares of Design Therapeutics during the 4th quarter valued at about $28,000. Nisa Investment Advisors LLC lifted its stake in Design Therapeutics by 38,433.3% in the fourth quarter. Nisa Investment Advisors LLC now owns 11,560 shares of the company’s stock valued at $31,000 after buying an additional 11,530 shares during the period. Federated Hermes Inc. boosted its holdings in shares of Design Therapeutics by 317.6% during the 4th quarter. Federated Hermes Inc. now owns 11,999 shares of the company’s stock worth $32,000 after buying an additional 9,126 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Design Therapeutics by 152.5% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,300 shares of the company’s stock worth $33,000 after buying an additional 3,201 shares during the period. Finally, Legal & General Group Plc increased its stake in shares of Design Therapeutics by 28.0% in the 2nd quarter. Legal & General Group Plc now owns 3,247 shares of the company’s stock valued at $45,000 after acquiring an additional 711 shares in the last quarter. 56.64% of the stock is currently owned by institutional investors and hedge funds.

Design Therapeutics Trading Down 2.1 %

DSGN opened at $3.69 on Friday. The company has a market cap of $208.46 million, a P/E ratio of -3.08 and a beta of 1.82. The company’s 50 day moving average is $3.02 and its 200-day moving average is $2.58. Design Therapeutics has a 1-year low of $1.94 and a 1-year high of $8.47.

Design Therapeutics (NASDAQ:DSGN) last issued its earnings results on Tuesday, March 19th. The company reported ($0.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.32) by $0.11. On average, equities analysts forecast that Design Therapeutics will post -1.25 EPS for the current year.

Design Therapeutics Company Profile

Design Therapeutics, Inc a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion.